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Abstract
Background: The hypothalamic-pituitary-adrenal stress axis plays a crucial role in community-acquired pneumonia
(CAP), with high cortisol being associated with disease severity and corticosteroid treatment resulting in earlier time
to recovery. Our aim in the present study was to compare different glucocorticoid hormones, including cortisol,
11-deoxycortisol, cortisone, and corticosterone, regarding their association with short- and long-term adverse
outcomes in a well-defined CAP cohort.
Methods: We prospectively followed 285 patients with CAP from a previous Swiss multicenter trial for a median of
6.1 years and measured different admission glucocorticoid serum levels by liquid chromatography coupled with
tandem mass spectrometry. We used adjusted Cox regression models to investigate associations between
admission hormone levels and all-cause mortality at different time points.
Results: Mortality was 5.3% after 30 days and increased to 47.3% after 6 years. High admission cortisol was
associated with adverse outcome after 30 days (adjusted OR 3.85, 95% CI 1.10–13.49, p = 0.035). In the long term
(i.e.,), however, high admission cortisol was associated with better survival (adjusted HR after 3 years 0.53, 95% CI 0.
32–0.89, p = 0.017; adjusted HR after 6 years 0.57, 95% CI 0.36–0.90, p = 0.015). Compared with 11-deoxycortisol,
cortisone, and corticosterone, cortisol showed the highest association with mortality.
Conclusions: Among different glucocorticoid hormones, cortisol showed the highest association with mortality in
CAP. Whereas a more pronounced glucocorticoid stress response on hospital admission was associated with higher
short-term adverse outcome, long-term outcome was favorable in these patients. These data should support the
correct interpretation of glucocorticoid blood data.
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Background
Activation of the hypothalamic-pituitary-adrenal (HPA)
axis and stimulation of the central noradrenergic stress
system by cytokines and other mediators are major
pathophysiological adaptations in response to infection
and inflammation [1–4]. Appropriate activation of the
HPA axis during illness is crucial for survival and mir-
rors the stress level. The effects of cortisol include pro-
tection against excessive inflammatory reaction, acute
supply of energy, and improvement in hemodynamic
status [5, 6].
Endogenous adrenocortical function is of prognostic
value in critical illness and sepsis [7–14], of which
community-acquired pneumonia (CAP) is a major source
[15–17]. Morbidity in CAP is still high also, owing to
higher risk for cardiovascular events [18, 19]. Researchers
in multiple studies have investigated the adrenal steroid
metabolism in relation to CAP-associated outcomes [14,
20–25]. In observational trials, researchers have reported
increased admission cortisol levels to be independent pre-
dictors of disease severity and short-term mortality in pa-
tients across the spectrum of mild to severe CAP [20–24].
Interestingly, the predictive accuracy of free cortisol was
not superior to that of total cortisol, independent of serum
albumin levels [20]. The prognostic accuracy of cortisol
levels in short-term mortality prediction was equal to that
of the pneumonia severity index (PSI), but better than the
CURB-65 score (confusion of new onset, blood urea
nitrogen >7 mmol/L, respiratory rate ≥30 breaths per mi-
nute, systolic blood pressure <90 mmHg or diastolic blood
pressure ≤60, and age ≥65 years) and routinely measured
laboratory parameters such as C-reactive protein (CRP),
procalcitonin (PCT), or white blood cell count [20, 21,
23]. In addition, in severe CAP, baseline serum cortisol
levels were shown to be independent predictors of
mortality with superior predictive ability compared with
stimulated cortisol with corticotropin or Δ-cortisol [24].
Despite evidence regarding short-term outcomes, less is
known about the predictive potential of glucocorticoid
levels in regard to long-term mortality. Aside from that,
most studies have been focused on cortisol only, and data
regarding other human glucocorticoids, such as 11-
deoxycortisol, cortisone, and corticosterone, are largely
lacking. Identification of patients at risk for adverse out-
come after an index hospitalization for CAP may optimize
in-hospital and post-acute care strategies to improve
survival. A better description of metabolite signatures in
CAP may improve pathophysiological understanding and
provide new targets for a more personalized therapy. In
the present study, our aim was to study different com-
pounds of the glucocorticoid pathway, including cortisol,
11-deoxycortisol, cortisone, and corticosterone, regarding
their association with short- and long-term adverse out-
comes in a well-defined CAP cohort.
Methods
Study design and setting
This is a secondary analysis of data from a prospective,
randomized, controlled multicenter trial performed at
six Swiss secondary or tertiary care centers between
October 2006 and March 2008 [26]. A detailed study
protocol of the initial trial has been published elsewhere
[27]. Briefly, from a total of 1825 potential patients, 925
subjects with CAP were included. The aim of the initial
trial was to assess the efficacy and safety of a PCT-guided
antibiotic therapy compared with standard guidelines
without using PCT data [28–30] in patients with CAP and
other lower respiratory tract infections [31]. The study
protocol was approved by the ethics committee of the
University of Basel as well as by all local ethics commit-
tees, and written informed consent was provided by all
participants for the initial trial, including agreement to use
their data anonymized in secondary analyses.
Selection and assessment of participants
Inclusion criteria were age >18 years and final diagnosis
of CAP with an infiltrate on a chest x-ray [31]. Exclusion
criteria were language restriction or dementia precluding
patients from providing written informed consent, pres-
ence of a terminal condition, and intravenous drug
abuse. For reasons of the initial antibiotic stewardship
trial, patients were excluded for severe immunosuppres-
sion or for long-term antibiotic therapy on admission in-
dependent of the current infection (e.g., in case of
endocarditis or chronic infections), whereas a require-
ment of corticosteroids or short-term antibiotic pretreat-
ment was allowed. All patients included in the analysis
were inpatients.
Patient assessment included clinical and biochemical
evaluation upon admission to the emergency department
(ED) and throughout the period of hospitalization. The
standardized baseline characteristics comprised medical
history, comorbidities (identified either through patient
self-report or medical chart review), vital signs including
fever (≥38.5 °C), laboratory values, chest x-ray, and
medication. To assess disease severity, the PSI [32] and
the CURB-65 score [29]—validated risk assessment tools
to categorize patients with CAP into different risk clas-
ses—were calculated upon ED admission. Confusion was
also assessed as part of these scores. Discharge decision
concerning patients enrolled in the study was left com-
pletely to the treating physicians without interference of
the study team. For the present study, 285 patients with
a final diagnosis of CAP and available serum blood spec-
imens [27, 31] were included.
Analysis of blood biomarker
Within the initial trial, blood samples from each patient
were collected and frozen upon ED admission for later
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measurement of different biomarkers. Cortisol, 11-
deoxycortisol, cortisone, and corticosterone levels were
measured in admission serum blood samples of all 285
included patients with CAP.
After internal validation studies, we determined concen-
trations of selected hormones using a commercially avail-
able kit (MassChrom Steroids; Chromsystems, Munich,
Germany). The analysis was performed using the UltiMate
3000 ultra-high-performance liquid chromatography
(UHPLC) system (Thermo Fisher Scientific, San Jose, CA,
USA) coupled to an AB Sciex 5500 quadrupole mass spec-
trometer (AB Sciex, Darmstadt, Germany). The Turbo V
ion source (AB Sciex) was operated in positive electrospray
ionization mode. The targeted screening method employed
the multiple reaction monitoring mode of operation using
two transitions for each analysis sample. Prior to injection
into the UHPLC system, serum samples were subjected to
a complex process of reversed phase 96-well solid-phase
extraction, purification, and concentration as described in
the MassChrom Steroids user’s manual. Quantification of
selected metabolites was achieved by reference to appropri-
ate internal standards. Concentrations of all analyzed me-
tabolites were reported in nanomoles per liter.
Main outcome measurements
The primary endpoint of this study was defined as 6-year
all-cause mortality. As secondary endpoints, we reported
mortality at days 30, 60, 90, 180, 240, and 300, as well as at
1 year, 2 years, and 3 years. Additional secondary endpoints
were 30-day adverse outcome (including all-cause mortality
and/or admission to the intensive care unit [ICU]) and dis-
ease severity defined by the PSI on admission. The decision
for ICU admission was left to the treating physicians.
To validate outcomes, we performed blinded, struc-
tured telephone interviews at 30, 180, and 540 days after
enrollment, as well as after a median of 6.1 years (IQR
5.6–6.5) [33, 34]. In cases where patients or their family
members could not be contacted, the treating general
practitioner was contacted.
Statistical analyses
Statistical analyses were conducted using STATA 12.1 soft-
ware (StataCorp, College Station, TX, USA). p Values <0.05
indicated statistical significance. Description of the study
population was performed with descriptive statistics, in-
cluding median with IQR to express continuous variables
and frequency (percent) for categorical variables. The Wil-
coxon rank-sum test was used for two-group comparison,
whereas frequency comparison was done by chi-square test.
All analyses were performed in the overall population.
Correlation analyses of glucocorticoid levels with inflam-
matory markers were calculated by Spearman’s rank correl-
ation. For multigroup comparisons, the Kruskal-Wallis test
was performed. Univariate and multivariate Cox regression
models were performed to investigate associations between
glucocorticoid levels and all-cause mortality at different time
points; these associations were reported as HR with 95% CI.
Before being entered into regression models, blood bio-
marker levels were log-transformed with a base of 10 due to
a skewed distribution; after logarithmic transformation, the
data approximated a normal distribution. Because of this
transformation, HRs and ORs correspond to a tenfold in-
crease in hormone levels. Kaplan-Meier curves were used to
illustrate mortality based on glucocorticoid quartiles (highest
versus lower three). To assess the association of glucocortic-
oid levels with other short-term adverse outcomes, we used
univariate and multivariate logistic regression models, re-
ported as OR with 95% CI. Significance levels were calcu-
lated by chi-square (Wald) test.
Models were adjusted for age, sex, and comorbidities (cor-
onary heart disease, cerebrovascular insult, chronic kidney
disease, neoplastic disease). The multivariate adjustment was
predefined on the basis of factors known to be associated
with mortality (age and comorbidities). We also included sex
in the model because of expected differences in adrenal hor-
mone levels based on gender. Initial randomization was not
significantly associated with study endpoints and was thus
not further considered for the statistical analysis.
Results
Patient population
Among a total of 285 patients with CAP, 135 (47.3%) died
during the 6-year follow-up period. The median age of the
entire cohort was 71 years, and 60.4% of patients were
male. There was a high burden of comorbidities, with
20.7% (n = 59) of patients having underlying coronary heart
disease, 15.4% (n = 44) having congestive heart failure,
23.5% (n = 67) having chronic renal failure, 19.3% (n = 55)
having diabetes mellitus, and 13.3% (n = 38) having neo-
plastic disease. We had blood levels available for cortisol in
227 patients (80%), for 11-deoxycortisol in 249 patients
(87%), for cortisone in 283 patients (99%), and for cortico-
sterone in 285 patients (100%). Additional baseline charac-
teristics of the entire cohort, stratified by the primary
endpoint as well as by 30-day adverse outcome, are shown
in Table 1 and Additional file 1: Table S1, respectively.
Importantly, compared with the study population of
the initial trial [26], including 925 patients with CAP
with an all-cause mortality of 45% over a follow-up
period of 6 years, the present analyzed cohort displayed
a similar pattern of baseline characteristics [34]. Mortal-
ity in this cohort was 5.3% after 30 days and increased to
20.7% and 47.3% after 3 years and 6 years, respectively.
Time-dependent association between glucocorticoid
levels and adverse outcome
Table 2 illustrates associations between admission serum
glucocorticoid levels and all-cause mortality in a time-
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Table 1 Baseline characteristics overall and stratified by 6-year vital status in community-acquired pneumonia
6-Year vital status
Characteristics Entire cohort (n = 285) Survivors (n = 150) Nonsurvivors (n = 135) p Value
Demographic characteristics
Age, years 71 [57–81] 64 [45–75] 79 [70–84] <0.001
Male sex 172 (60.4%) 80 (53.3%) 92 (68.1%) 0.011
CAP characteristics
PSI class
I 32 (11.2%) 30 (20.0%) 2 (1.5%) <0.001
II 55 (19.3%) 44 (29.3%) 11 (8.1%) <0.001
III 52 (18.2%) 29 (19.3%) 23 (17.0%) 0.62
IV 104 (36.5%) 38 (25.3%) 66 (48.9%) <0.001
V 42 (14.7%) 9 (6.0%) 33 (24.4%) <0.001
CURB-65 score
0 63 (22.1%) 51 (34.0%) 12 (8.9%) <0.001
I 67 (23.5%) 41 (27.3%) 26 (19.3%) 0.11
II 82 (28.8%) 33 (22.0%) 49 (36.3%) 0.008
III 57 (20.0%) 21 (14.0%) 36 (26.7%) 0.008
IV/V 16 (5.6%) 4 (2.7%) 12 (8.9%) 0.023
Comorbiditiesa
Coronary heart disease 59 (20.7%) 16 (10.7%) 43 (31.9%) <0.001
Congestive heart failure 44 (15.4%) 7 (4.7%) 37 (27.4%) <0.001
Cerebrovascular insult 28 (9.8%) 9 (6.0%) 19 (14.1%) 0.022
PAOD 17 (6.0%) 7 (4.7%) 10 (7.4%) 0.33
Chronic renal failure 67 (23.5%) 19 (12.7%) 48 (35.6%) <0.001
Diabetes mellitus 55 (19.3%) 22 (14.7%) 33 (24.4%) 0.037
Neoplastic disease 38 (13.3%) 12 (8.0%) 26 (19.3%) 0.005
Clinical history
Fever 185 (65.1%) 113 (75.3%) 72 (53.7%) <0.001
Chills 87 (34.0%) 58 (42.0%) 29 (24.6%) 0.003
Glucocorticoid pretreatment 22 (7.9%) 5 (3.4%) 17 (12.9%) 0.003
Clinical findings
Confusion 20 (7.9%) 4 (2.9%) 16 (13.7%) 0.002
Body temperature, °C 38 [37.2–38.8] 38.2 [37.4–39] 37.8 [37–38.8] 0.085
Breath rate, breaths/minute 20 [16–25] 20 [16–24] 24 [18–28] 0.002
Heart rate, beats/minute 94 [82–105] 92.5 [83.5–108] 95 [80–104] 0.43
SBP, mmHg 130 [117–148] 130 [120–148] 130 [110–149] 0.17
Arterial pH 7.46 [7.42–7.49] 7.46 [7.43–7.50] 7.45 [7.41–7.49] 0.013
SIRS criteria 188 (66.0%) 93 (62.0%) 95 (70.4%) 0.14
Outcome parameters
ICU admission 21 (7.4%) 9 (6.0%) 12 (8.9%) 0.35
Mechanical ventilation 7 (2.5%) 2 (1.3%) 5 (3.7%) 0.20
Septic shock 6 (2.1%) 1 (0.7%) 5 (3.7%) 0.075
Length of stay, days 8 [5–12] 7 [4–10] 9 [6–13] <0.001
Admission laboratory findings
CRP, mg/L 132 [65–252] 147 [91–265] 111 [55–249] 0.037
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dependent manner. In the short term, all glucocorticoid
hormones had HRs >1 and thus tended to be associated
with higher mortality risk, but these associations chan-
ged over time. We found high initial cortisol and corti-
sone levels to be significantly associated with lower risk
for 6-year mortality with HRs of 0.63 (95% CI 0.41–0.99;
p = 0.045) and 0.60 (95% CI 0.38–0.95; p = 0.030), re-
spectively. For 3-year mortality, results were similar with
HRs of 0.54 (95% CI 0.32–0.90; p = 0.018) and 0.56 (95%
CI 0.33–0.94; p = 0.028) for cortisol and cortisone, re-
spectively. For cortisol, these associations remained ro-
bust after adjustment for age, sex, and comorbidities.
These results are also presented in Fig. 1, where a step-
wise decrease in HRs with longer observation time for
cortisol and cortisone, and to a lesser extent also for 11-
deoxycortisol and corticosterone, can be observed. We
further show Kaplan-Meier curves for 6-year survival
stratified by glucocorticoid-level quartiles (Fig. 2). The
highest quartile of admission cortisol and cortisone
levels was favorably associated with long-term survival.
Also, high initial levels of cortisol were independently as-
sociated with higher risk for short-term adverse outcome
(defined as risk for mortality and/or ICU admission) with
an adjusted OR of 3.85 (95% CI 1.10–13.49; p = 0.035)
(Table 3).
Association between glucocorticoid levels and severity
of CAP
Multigroup comparison using the Kruskal-Wallis test
showed a gradual increase in initial 11-deoxycortisol levels
Table 1 Baseline characteristics overall and stratified by 6-year vital status in community-acquired pneumonia (Continued)
PCT, μg/L 0.48 [0.16–3.20] 0.64 [0.16–3.72] 0.43 [0.16–1.97] 0.37
Cortisol, nmol/L 402 [203.8–723.2] 431 [189.1–759.2] 399 [213.1–710.3] 0.46
11-Deoxycortisol, nmol/L 0.6 [0.17–2.23] 0.4 [0.16–2.13] 0.8 [0.18–2.25] 0.49
Cortisone, nmol/L 32.5 [18.42–46.72] 33.2 [19.28–48.49] 32.4 [17.68–44.41] 0.29
Corticosterone, nmol/L 8.7 [2.81–25.02] 8.9 [2.73–28.67] 8.4 [3.13–22.95] 0.85
Abbreviations: CAP Community-acquired pneumonia, CRP C-reactive protein, CURB-65 Confusion of new onset, blood urea nitrogen >7 mmol/L, respiratory rate ≥30
breaths per minute, systolic blood pressure <90 mmHg or diastolic blood pressure ≤60, and age ≥65 years, PAOD Peripheral arterial occlusive disease, PCT
Procalcitonin, PSI Pneumonia severity index, SBP Systolic blood pressure, SIRS Systemic inflammatory response syndrome, ICU Intensive care unit
Data are presented as median [IQR] or number (percent); p < 0.05 is considered statistically significant. Bold values indicate statistical significance
aComorbidities were identified on the basis of medical records or patient report
Table 2 Association of admission glucocorticoid levels with short- and long-term all-cause mortality in community-acquired
pneumonia
Entire cohort (N = 285) All-cause mortality time point
30 days 3 years 6 years
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Cortisol
Cox regression analyses
Univariate model 2.47 (95% CI 0.50–12.18) 0.268 0.54 (95% CI 0.32–0.9) 0.018 0.63 (95% CI 0.41–0.99) 0.045
Multivariate modela 1.93 (95% CI 0.51–9.02) 0.405 0.53 (95% CI 0.32–0.89) 0.017 0.57 (95% CI 0.36–0.90) 0.015
11-Deoxycortisol
Cox regression analyses
Univariate model 1.37 (95% CI 0.75–2.53) 0.309 0.95 (95% CI 0.76–1.18) 0.631 1.04 (95% CI 0.86–1.24) 0.710
Multivariate modela 1.26 (95% CI 0.65–2.44) 0.486 0.84 (95% CI 0.67–1.05) 0.126 0.91 (95% CI 0.75–1.1) 0.336
Cortisone
Cox regression analyses
Univariate model 1.37 (95% CI 0.31–6.02) 0.677 0.56 (95% CI 0.33–0.94) 0.028 0.6 (95% CI 0.38–0.95) 0.030
Multivariate modela 2.55 (95% CI 0.38–17.30) 0.337 0.71 (95% CI 0.4–1.25) 0.237 0.76 (95% CI 0.46–1.24) 0.272
Corticosterone
Cox regression analyses
Univariate model 1.33 (95% CI 0.63–2.81) 0.457 0.77 (95% CI 0.57–1.03) 0.082 0.85 (95% CI 0.66–1.09) 0.199
Multivariate modela 1.21 (95% CI 0.55–2.65) 0.637 0.76 (95% CI 0.57–1.02) 0.067 0.81 (95% CI 0.63–1.03) 0.084
Data for univariate and multivariate Cox regression models are presented as HR (95% CI), p value; p < 0.05 is considered statistically significant. Bold values
indicate statistical significance. All hormone levels were log-transformed, and thus the HR corresponds to a tenfold increase in these levels
aMultivariate model is adjusted for age, sex, and comorbidities (coronary artery disease, cerebrovascular disease, chronic kidney disease, neoplastic disease)
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Fig. 1 (See legend on next page.)
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with increasing CAP severity as assessed by PSI classes
(p = 0.001) (illustrated in Fig. 3). Contrarily, there was
no similar increase in levels of cortisol, cortisone, and
corticosterone with PSI. However, for cortisol, there
was a trend of increasing hormone levels in more se-
verely ill patients.
Correlation between glucocorticoid levels and
inflammatory markers
As presented in Fig. 4, we found a correlation between
admission cortisol levels and high peak CRP (r = +0.22; p
= 0.001) and initial PCT values (r = +0.31; p < 0.001). Corti-
sone levels were also positively correlated with CRP levels
(r = +0.14; p = 0.023), whereas 11-deoxycortisol and cor-
ticosterone were significantly correlated with PCT levels
(r = +0.30 and +0.20, respectively; p < 0.001 for both).
Discussion
The key findings of our present study of the prognostic
value of different glucocorticoid hormones over a follow-up
period of 6 years in patients with CAP are threefold. First,
among different glucocorticoid hormones, cortisol showed
the highest association with outcome in the short and long
term. Second, the association of different glucocorticoid
metabolites with adverse outcome inversely changed over
time; whereas high levels of cortisol on initial hospital
presentation were independently associated with short-term
adverse outcome, a more pronounced initial glucocorticoid
stress response was associated with favorable long-term out-
come. Third, admission levels of 11-deoxycortisol showed
the best correlation with disease severity.
The HPA stress axis plays an important role in patients
with CAP, with cortisol being associated with short-term
outcome [20–24] and corticosteroid treatment that might
result in earlier time to recovery [35]. The release of
cortisol in acute illness is essential for improvement in
hemodynamic status, acute supply of energy, and protec-
tion against excessive inflammatory reaction [5, 6]. Im-
portantly, the acute stress response involves activation of
the glucocorticoid pathway and the adrenergic system,
resulting in tachycardia, increased myocardial oxygen con-
sumption, and probably enhanced platelet aggregation,
which might translate into acute myocardial infarction,
thus potentially raising short-term mortality [18]. Owing
to its positive correlation with the degree of illness-
induced stress [36], cortisol has been presumed to be a
prognostic marker mirroring characteristics of acute crit-
ical disease and disease progression. Considering cortisol
as the strongest inhibitor of inflammation, a higher level
of proinflammatory cytokines in acute illness could lead
to a more pronounced increase in cortisol [1–3, 37]. On
the basis of several clinical observational studies [20–24],
(See figure on previous page.)
Fig. 1 Association of admission glucocorticoid levels with all-cause mortality at different time points in CAP. Data for multivariate Cox regression
models are presented as HR (95% CI). HRs >1 reflect a positive association between glucocorticoid levels and all-cause mortality. Multivariate
model is adjusted for age, sex, and comorbidities (coronary artery disease, cerebrovascular disease, chronic kidney disease, neoplastic disease).
CAP Community-acquired pneumonia
Fig. 2 Kaplan-Meier 6-year survival estimate according to admission glucocorticoid levels in CAP: fourth versus first-to-third quartiles. CAP
Community-acquired pneumonia
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Table 3 Association of admission glucocorticoid levels with short-term adverse outcome in community-acquired pneumonia
Entire cohort (N = 285) Adverse outcome at 30 days (death and/or ICU admission)
OR (95% CI) p Value
Cortisol
Logistic regression analyses
Univariate model 4.16 (95% CI 1.22–14.12) 0.022
Multivariate modela 3.85 (95% CI 1.10–13.49) 0.035
11-Deoxycortisol
Logistic regression analyses
Univariate model 1.33 (95% CI 0.84–2.11) 0.216
Multivariate modela 1.30 (95% CI 0.80–2.14) 0.293
Cortisone
Logistic regression analyses
Univariate model 1.89 (95% CI 0.59–1.03) 0.280
Multivariate modela 3.25 (95% CI 0.84–12.68) 0.089
Corticosterone
Logistic regression analyses
Univariate model 1.41 (95% CI 0.81–2.47) 0.225
Multivariate modela 1.44 (95% CI 0.79–2.62) 0.234
ICU, Intensive care unit
Data for univariate and multivariate logistic regression models are presented as OR (95% CI), p value; p < 0.05 is considered statistically significant. Bold values
indicate statistical significance. All hormone levels were log-transformed, and thus the OR corresponds to a tenfold increase in levels






Fig. 3 Glucocorticoid levels in patients with various severity classes of CAP. Data represent median and IQR, with scatter plots presenting all
values. P values are determined by Kruskal-Wallis test and considered statistically significant at p < 0.05. Bold values indicate statistical significance.
CAP Community-acquired pneumonia, PSI Pneumonia severity index
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cortisol levels have lately emerged as a useful prognostic
tool regarding short-term mortality. The present analysis
of a large, well-characterized cohort provides novel
insights into the role of the glucocorticoid pathway in
regard to adverse outcome in hospitalized patients with
mild to severe CAP.
Regarding short-term outcome, our findings are in line
with previous data derived from clinical observational
studies suggesting that high levels of cortisol ae associated
with mortality in CAP [20–24]. In our study, high
admission cortisol levels were independently associated
with short-term adverse outcome, including the combined
endpoint mortality/ICU admission. Association of cortisol
levels with 30-day all-cause mortality alone showed a simi-
lar trend; likely due to the small event number, the results
did not reach statistical significance.
Interestingly, a more pronounced initial glucocorticoid
host response was beneficial for long-term survival. For
Fig. 4 Correlation of admission glucocorticoid levels with inflammatory markers in CAP. Data are presented with scatterplots showing all values
(blue), overlaid by linear fit lines (red). Correlation analyses were performed by Spearman’s rank correlation (r; p value). We used multivariate linear
regression models to calculate regression coefficients (Coef.). p < 0.05 is considered statistically significant. Bold values indicate statistical
significance. We used admission glucocorticoid and PCT levels and high peak CRP levels. CAP Community-acquired pneumonia, CRP C-reactive
protein, PCT Procalcitonin. *Multivariate model is adjusted for age, sex, and comorbidities (coronary artery disease, cerebrovascular disease, chronic
kidney disease, neoplastic disease)
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cortisol, this effect remained robust after adjustment for
potential confounders. Because most previous studies
have demonstrated a strong HPA stress axis response to
be positively associated with adverse short-term out-
comes [20–24], the present findings are somewhat
counterintuitive. Hypothesizing that high levels of
proinflammatory cytokines lead to an increase in cortisol
[1–3, 37] to avoid excessive inflammation, a more pro-
nounced initial glucocorticoid response might reflect not
only the degree of stress but also the ability to generate
an adequate immune response. Within this study, we
demonstrated an independent correlation between ad-
mission cortisol levels and markers of inflammation
(PCT and high peak CRP). From this point of view, our
findings are in line with those of a previous study dem-
onstrating a more pronounced inflammatory host re-
sponse reflected by a history of chills, high body
temperature, and high peak levels of CRP being associ-
ated with lower long-term mortality in patients surviving
a CAP episode [38]. These results were similar to those
of the Pneumonia Patient Outcomes Research Team co-
hort study, another large follow-up study of patients
with CAP, in which researchers reported an association
between the absence of fever and higher long-term mor-
tality than among age-matched control subjects [39].
Contrarily, several studies have shown an association
between worse short-term outcomes and strong inflam-
matory response in CAP [40–42]. On the basis of these
data, it is tempting to hypothesize that survival of a clin-
ically and biochemically pronounced CAP episode—re-
flected by high admission glucocorticoid levels—might
mirror a more robust stress response, and, concordantly,
also host defense, and thus a better general condition
with lower mortality in the long term. However, a
pronounced glucocorticoid response on admission might
reflect, as a presumable consequence of inflammation,
the ability to generate an appropriate immune response,
thereby predisposing these “fitter” patients, with regard
to the stress-response, to better long-term survival
owing to decreased subsequent infections [43]. Further
investigations are still warranted to validate these find-
ings and determine underlying pathophysiology. Given
the evidence of pronounced inflammation being associ-
ated with favorable long-term outcome in hospitalized
patients with CAP, the rationale of steroid treatment in
this population should be questioned.
The main strengths of this study include the well-
characterized cohort of patients hospitalized for CAP, the
long follow-up period of approximately 6 years, and the
thorough and highly accurate biomarker measurement by
liquid chromatography coupled with tandem mass spec-
trometry. This technique allows a proper separation and
sensitive characterization of even small molecules [44].
Importantly, mass spectrometry is increasingly becoming
accepted as a routine diagnostic instrument in clinical
laboratories [45]. Furthermore, the large sample size and
the high event number of the primary endpoint (47.3%)
lead to high statistical power, which allows detecting even
small differences in glucocorticoid levels.
The following limitations require consideration. First,
the present study is a secondary analysis and therefore not
designed primarily to perform observational biomarker
outcome studies. Importantly, there was no controlling
for the time point of blood sampling, because initial blood
samples were taken at the time of first patient contact in
the ED. However, although cortisol exhibits diurnal
concentration changes, during acute illness, the circadian
pattern is usually lost [5, 46, 47]. Also, the long storage of
blood may have affected blood hormone levels. In
addition, there was no assessment of adrenal insufficiency
based on the response to injection of synthetic adrenocor-
ticotropin. Nevertheless, previous data demonstrated a
very low rate of adrenal insufficiency in patients with CAP
in the absence of septic shock [23]. However, deviation of
the present results by different blood sampling time points
or adrenal insufficiency cannot be definitively ruled out,
although this lack of standardization reflects daily clinical
practice. A more standardized hormone level determin-
ation at the same time of the day in all patients would
most probably have demonstrated an even higher associ-
ation between glucocorticoid levels and CAP outcomes.
Moreover, serial hormone measurements over the course
of the disease may add valuable information.
Second, the initial trial was conducted in different
secondary and tertiary care hospitals in Switzerland, and
thus results may not unconditionally be applied to other
geographical or institutional settings. In addition, our ana-
lysis was focused specifically on patients with CAP;
further studies are required to validate these findings
for other medical and surgical patient populations.
Finally, because this was an observational study, it is
only hypothesis-generating, and correlation does not
imply a causal relationship.
Conclusions
Cortisol showed the highest association with outcome in
patients with mild to severe CAP. The association of the
glucocorticoid levels with adverse outcome in patients with
CAP changed over time; whereas high admission levels of
cortisol were independently associated with short-term
adverse outcome, a more pronounced initial glucocorticoid
stress response was highly associated with favorable long-
term outcome. Initial 11-deoxycortisol levels showed the
highest correlation with disease severity. Underlying patho-
physiological aspects are still poorly examined, and future
studies are needed to better understand the importance of
adrenal hormones in the resolution of patients with CAP.
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Key messages
 Among different glucocorticoid hormones, cortisol
showed the highest association with mortality in
patients with CAP.
 The association of glucocorticoid metabolites with
outcome in CAP changed over time; whereas a
more pronounced glucocorticoid stress response on
initial hospital presentation was associated with
higher short-term adverse outcome, increased
admission hormone levels showed association with
favorable long-term outcome.
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